Holen Sie sich die Stockscreener-App
77.56
0.63%
-0.49
Vorhandelsmarkt:
77.26
-0.30
-0.39%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$78.05
Offen:
$77.91
24-Stunden-Volumen:
3.40M
Relative Volume:
0.80
Marktkapitalisierung:
$240.54B
Einnahmen:
$56.53B
Nettoeinkommen (Verlust:
$8.32B
KGV:
28.94
EPS:
2.6798
Netto-Cashflow:
$8.49B
1W Leistung:
-4.51%
1M Leistung:
-2.03%
6M Leistung:
-0.05%
1J Leistung:
-1.87%
1-Tages-Spanne:
$77.24
$78.02
1-Wochen-Bereich:
$77.24
$81.31
52-Wochen-Spanne:
$61.24
$82.41
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
77.56 | 241.99B | 56.53B | 8.32B | 8.49B | 2.6798 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca reports positive Phase III results for Saphnelo in lupus trial - Investing.com
AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease - stocktwits.com
AstraZeneca Says Phase 3 Trial of Fasenra in COPD Fails to Meet Primary Endpoint - MarketScreener
Canandaigua National Bank & Trust Co. Has $1.38 Million Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Asthma Drug Fails COPD Study for a Second Time - Bloomberg.com
AstraZeneca says Fasenra misses main goal in COPD trial By Investing.com - Investing.com UK
AstraZeneca lupus drug Saphnelo shows promise in self-injection trial - Proactive Investors
AstraZeneca's asthma drug fails 'smoker's lung' study - Reuters
AstraZeneca's Systemic Lupus Erythematosus Medicine Meets Primary Endpoint in Late-stage Trial - MarketScreener
AstraZeneca's Fasenra Fails to Meet Primary Endpoint in Pulmonary Disease Trial - MarketScreener
AstraZeneca's asthma drug fails main goal of COPD study - MarketScreener
AstraZeneca : Saphnelo met primary endpoint in TULIP-SC - MarketScreener
AstraZeneca : Update on RESOLUTE Phase III trial - MarketScreener
Investment crisis: AstraZeneca halts $271m UK expansion - BioXconomy
Retail Trends: Should I hold or sell AstraZeneca PLC Depositary Receipt now2025 Analyst Calls & Fast Gaining Stock Reports - خودرو بانک
Value Recap: Should I hold or sell AstraZeneca PLC Depositary Receipt nowJuly 2025 PostEarnings & Stepwise Trade Execution Plans - خودرو بانک
Acadian Asset Management LLC Sells 48,052 Shares of AstraZeneca PLC $AZN - MarketBeat
Bull Bear: Can AstraZeneca PLC Depositary Receipt expand into new marketsWeekly Trade Report & Expert Curated Trade Setup Alerts - خودرو بانک
AstraZeneca Sales, Profit Outshine Estimates on Cancer Drugs - MSN
Aug Sentiment: Is AstraZeneca PLC Depositary Receipt vulnerable to short sellersLayoff News & Smart Money Movement Alerts - خودرو بانک
Wesbanco Bank Inc. Boosts Stock Position in AstraZeneca PLC $AZN - MarketBeat
Canandaigua National Trust Co of Florida Has $784,000 Stake in AstraZeneca PLC $AZN - MarketBeat
Ascent Group LLC Acquires New Holdings in AstraZeneca PLC $AZN - MarketBeat
Goldman Sachs raises AstraZeneca stock price target on HPP drug potential - Investing.com UK
Focus Partners Wealth Has $5.85 Million Stake in AstraZeneca PLC $AZN - MarketBeat
Q4 EPS Estimates for AstraZeneca Increased by Zacks Research - MarketBeat
Momentum Shift: Why is AstraZeneca PLC Depositary Receipt stock going upWeekly Trading Summary & Weekly Watchlist of Top Performers - خودرو بانک
Short Covering: Is AstraZeneca PLC Depositary Receipt gaining market share2025 Historical Comparison & High Return Stock Watch Alerts - خودرو بانک
AstraZeneca drags FTSE 100 lower ahead of key central bank decisions - MarketScreener
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit - Benzinga
AstraZeneca PLC (AZN) Receives Tagrisso Boost in Lung Cancer Trials - Yahoo Finance
AstraZeneca halts £200m research investment in Cambridge - Yahoo Finance
AstraZeneca shares down 3% after rating cut, UK investment pause - Reuters
AstraZeneca, strong sterling drag FTSE 100 lower ahead of key central bank decisions - MarketScreener
Trade Report: Is HTLM stock undervalued right nowJuly 2025 Chart Watch & Free Safe Capital Growth Stock Tips - خودرو بانک
AstraZeneca falls 3% as £200m Cambridge expansion put on hold By Investing.com - Investing.com Nigeria
AstraZeneca falls 3% as £200m Cambridge expansion put on hold - Investing.com
AstraZeneca Pauses $271 Million Cambridge Project - MarketScreener
Ashton Thomas Private Wealth LLC Makes New Investment in AstraZeneca PLC $AZN - MarketBeat
365,000 Shares in AstraZeneca PLC $AZN Acquired by Strs Ohio - MarketBeat
Integrity Alliance LLC. Makes New $440,000 Investment in AstraZeneca PLC $AZN - MarketBeat
Exome Asset Management LLC Invests $2.39 Million in AstraZeneca PLC $AZN - MarketBeat
Growth Value: Whats the outlook for AstraZeneca PLC Depositary Receipts sectorWeekly Trade Analysis & Community Consensus Trade Alerts - خودرو بانک
AstraZeneca pauses £200 million investment in new research facility - MarketScreener
AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site - MarketScreener
AstraZeneca PLC $AZN Shares Bought by Fred Alger Management LLC - MarketBeat
Voya Investment Management LLC Acquires 443,795 Shares of AstraZeneca PLC $AZN - MarketBeat
Q2 EPS Estimates for AstraZeneca Increased by Zacks Research - MarketBeat
Howe & Rusling Inc. Sells 35,353 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Suspends UK Investment Plans Worth GBP200 Million - MarketScreener
AstraZeneca pauses £200m expansion in Cambridge - MSN
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):